Clinical trials: ALK+ Non-Small-Cell Lung Carcinoma, open to volunteers
ALK+ Non-Small-Cell Lung Carcinoma
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context
- Trial name
- LOREA (NCT06487078)
- Testing
- Lorlatinib
- Where
- 32 sites in France
- Volunteers
- 90 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty.
- Trial name
- NCT07140016
- Testing
- gilteritinib
- Where
- 17 sites in United States, France and 1 more
- Volunteers
- 40 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
The treatment decisions, assessment schedule, and study procedures in this research will adhere to the routine clinical practice of each participating center.
- Conditions
- Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative, Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2, No Prior Systemic Therapy Received for the Advanced or Metastatic Disease
- Trial name
- PROMISE (NCT07696832)
- Testing
- Ivonescimab Injection
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Guangdong Association of Clinical Trials
ALK Positive Non-small Cell Lung Cancer
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as…
- Trial name
- NCT07617337
- Testing
- AQUA07, Lorlatinib
- Where
- 7 sites in United States, Japan
- Volunteers
- 102 people
- Sponsor
- Chugai Pharmaceutical
ALK-positive NSCLC, ALK-Positive Lung Cancer
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC).
- Conditions
- ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
- Trial name
- NCT07491497
- Testing
- TRI-611
- Where
- 16 sites in United States, Australia
- Volunteers
- 160 people
- Sponsor
- TRIANA Biomedicines, Inc.
ALK Positive, ALK Positive Non-small Cell Lung Cancer
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)
- Conditions
- ALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC, ALK+ Non-Small-Cell Lung Carcinoma
- Trial name
- NCT07784959
- Testing
- NXP900, Lorlatinib
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Nuvectis Pharma, Inc.
ALK-positive Non Small Cell Lung Cancer
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
This is a single-arm clinical study planning to enroll 30 treatment-naive patients with resectable ALK-positive non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT07771764
- Testing
- iruplaltinib and pemetrexed
- Where
- 7 sites in China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
ALK Positive Non-small Cell Lung Cancer
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China.
- Trial name
- NCT07750704
- Testing
- Lorlatinib, sacituzumab tirumotecan plus lorlatinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Guangdong Association of Clinical Trials
NSCLC Stage IV, ALK Fusion Protein Expression
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
- Trial name
- ARCHER (NCT05950139)
- Testing
- Peptide vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ALK Fusion-positive Non-small Cell Lung Cancer
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
This prospective single-arm clinical study plans to enroll 29 participants with unresectable stage IIIB-IV ALK fusion-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT07674368
- Testing
- Recaticimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Hunan Cancer Hospital
Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
For Patients and Families Brief Title: Management of 1L Lorlatinib with Hyperlipidemia in ALK+ Advanced NSCLC What is this study about? This study is for people with ALK-positive non-small cell lung cancer (NSCLC) who are taking…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia, ALK Gene Mutation, ALK-positive
- Trial name
- NCT07674524
- Testing
- For Part A - Observational Cohort:, Part B: Intensive Lipid-Lowering Group, For Part B - Intensive Group
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC
ALK TKIs, particularly second- and third-generation ALK TKIs, have significantly improved progression-free survival (PFS) in patients with advanced ALK-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT07671560
- Testing
- Combined group of ensatinib and arotinib
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Qiming Wang
Advanced ALK/ROS1-positive NSCLC, Carcinoma, Non-Small-Cell Lung (NSCLC)
Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
This observational study evaluates whether vortioxetine - an antidepressant medication with cognitive-enhancing properties - can reduce the neurological and cognitive side effects associated with lorlatinib treatment in patients…
- Conditions
- Advanced ALK/ROS1-positive NSCLC, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Adenocarcinoma, ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT07633626
- Where
- Colombia
- Volunteers
- 24 people
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
BioEXALK is a prospective study evaluating the biological characteristics of advanced ALK-rearranged NSCLC treated with next generation TKIs in first line, included in the national EXPLORE ALK cohort (GFPC 03-2019), a…
- Trial name
- BIOEXALK (NCT05122806)
- Testing
- RNAseq
- Where
- 46 sites in France
- Volunteers
- 100 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Non-small Cell Lung Cancer Stage IIIB, ALK Gene Mutation
Alectinib Pharmacokinetic in Patients With NSCLC
This interventional study aims to determine the pharmacokinetics of orally administered alectinib with dose escalation from 300 mg to 600 mg twice daily in Mexican patients with advanced ALK-positive NSCLC.
- Trial name
- NCT05713006
- Testing
- Alectinib Oral Product
- Where
- Mexico
- Volunteers
- 45 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Metastatic ALK+ Non Small Cell Lung Cancer
Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
The objective of this study is to monitor the usage of Lorviqua in real practice within label, including the adverse events associated with Lorviqua
- Trial name
- NCT05599412
- Testing
- Lorviqua
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Pfizer
Oncogene-addicted Non Small Cell Lung Cancer, EGFR Mutation
Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
Currently, tyrosine kinase inhibitor (TKI) remains the standard of care for oncogene-driven non-small cell lung cancer (NSCLC). However, almost all oncogene-driven NSCLCs would develop acquired resistance against TKI in clinical…
- Conditions
- Oncogene-addicted Non Small Cell Lung Cancer, EGFR Mutation, ALK Fusion-positive Solid or CNS Tumors, ROS1 Fusion Positive
- Trial name
- NCT07122882
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms…
- Conditions
- Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation
- Trial name
- NCT03042221
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Colorado, Denver
Non-Small Cell Lung Cancer, ALK
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy.
- Conditions
- Non-Small Cell Lung Cancer, ALK, Iruplinalkib, Lorlatinib
- Trial name
- SAILOR (NCT07374614)
- Testing
- Iruplinalkib tablets
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Shenzhen Hospital